Molecular mechanisms underlying mifepristone's agonistic action on ovarian cancer progression.

ABSTRACT:

Background

Recent clinical trials on ovarian cancer with mifepristone (MF) have failed, despite in vitro findings on its strong progesterone (P4) antagonist function.

Methods

Ovarian cancer human and murine cell lines, cultured high-grade human primary epithelial ovarian cancer (HG-hOEC) cells and their explants; as well as in vivo transgenic mice possessing ovarian cancer were used to assess the molecular mechanism underlying mifepristone (MF) agonistic actions in ovarian cancer progression.

Findings

Herein, we show that ovarian cancer cells express traceable/no nuclear P4 receptor (PGR), but abundantly P4 receptor membrane component 1 (PGRMC1). MF significantly stimulated ovarian cancer cell migration, proliferation and growth in vivo, and the translocation of PGRMC

SUBMITTER: Ponikwicka-Tyszko D 

PROVIDER: S-EPMC6796594 | biostudies-literature | 2019 Sep

REPOSITORIES: biostudies-literature